Axonics (Nasdaq:AXNX) has announced it received regulatory approval in Australia for its R20 rechargeable sacral neuromodulation (SNM) system, offering a new option for patients suffering from overactive bladder or fecal incontinence. The implantable system aims to improve the quality of life for individuals affected by these conditions.
The R20 neurostimulator maintains the compact 5cc form factor of the previous R15 generation, utilizing the same tined lead and patient remote control. Enhancements include improved programming capabilities and expanded MRI labeling, providing greater flexibility for patients and healthcare providers.
A key feature of the R20 is its extended functional life of at least 20 years, coupled with a reduced charging frequency of once every 6-10 months for just one hour. This advancement aims to minimize patient burden and improve adherence to therapy.
Regulatory Milestones and Market Expansion
Axonics previously obtained FDA approval for the R20 in January 2023 and secured CE mark in March 2024. The company initiated commercial activities in Australia in March 2023 and has already received regulatory approval to market its F15 recharge-free SNM system in the country. Axonics also markets Bulkamid hydrogel for female stress urinary incontinence in Australia, further solidifying its presence in the region.
Launch Plans and Leadership Perspective
Axonics intends to commence sales of the R20 system to Australian customers in November. Raymond W. Cohen, CEO of Axonics, stated, "We are delighted to receive regulatory approval for our latest rechargeable SNM system in Australia. Our mission-driven team remains committed to innovating, supporting our dedicated physician customers and their patients, and raising awareness of our best-in-class incontinence therapies."
